Mast Therapeutics, Inc. (NASDAQ:SVRA) has received an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.

Analysts have set a 1-year consensus price objective of $18.00 for the company, according to Zacks. Zacks has also assigned Mast Therapeutics an industry rank of 101 out of 265 based on the ratings given to its competitors.

SVRA has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Mast Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Thursday, August 24th. Canaccord Genuity initiated coverage on shares of Mast Therapeutics in a research report on Wednesday, June 7th. They set a “buy” rating and a $18.00 price target on the stock.

Shares of Mast Therapeutics (SVRA) traded down 1.12% on Friday, reaching $5.30. 35,113 shares of the company were exchanged. The company’s 50 day moving average is $5.78 and its 200 day moving average is $5.89. Mast Therapeutics has a 12-month low of $4.60 and a 12-month high of $49.62. The firm’s market capitalization is $73.18 million.

In related news, insider Jaakko Taneli Jouhikainen acquired 10,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $49,875.00. Following the completion of the acquisition, the insider now owns 235,326 shares of the company’s stock, valued at approximately $1,117,798.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph S. Mccracken acquired 52,250 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were bought at an average price of $4.75 per share, with a total value of $248,187.50. Following the acquisition, the director now directly owns 59,866 shares of the company’s stock, valued at approximately $284,363.50. The disclosure for this purchase can be found here. Insiders have purchased 64,850 shares of company stock worth $308,038 over the last three months. 4.26% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Zacks: Mast Therapeutics, Inc. (SVRA) Given Consensus Rating of “Buy” by Brokerages” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/zacks-mast-therapeutics-inc-svra-given-consensus-rating-of-buy-by-brokerages/1534704.html.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Get a free copy of the Zacks research report on Mast Therapeutics (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.